Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$1.61
-6.4%
$1.38
$0.87
$6.78
$160.98M0.74837,051 shs254,301 shs
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$14.52
-5.4%
$14.29
$10.57
$33.33
$2.11B1.331.36 million shs1.69 million shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$1.15
-0.9%
$1.20
$0.66
$5.92
$131.79M2.182.22 million shs1.02 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$57.15
-0.8%
$55.11
$42.01
$70.50
$7.04B1.152.01 million shs1.24 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$38.02
-1.2%
$39.28
$29.17
$62.40
$7.08B1.061.67 million shs1.40 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
+4.24%+16.61%+8.18%+81.05%-65.74%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
+2.33%+4.46%+0.59%+20.87%-29.10%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
+0.87%+1.31%-30.54%+9.43%-62.82%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+1.86%+6.62%+7.18%-4.30%+8.82%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-0.05%+4.05%-8.29%+7.78%-9.33%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alector, Inc. stock logo
ALEC
Alector
4.1099 of 5 stars
3.13.00.04.52.62.50.0
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
4.722 of 5 stars
4.52.00.04.73.82.50.0
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
4.1992 of 5 stars
3.13.00.04.72.61.70.6
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
4.615 of 5 stars
2.11.00.04.42.72.54.4
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4.5678 of 5 stars
4.52.00.04.73.21.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alector, Inc. stock logo
ALEC
Alector
2.14
Hold$4.00144.95% Upside
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
3.06
Buy$33.71125.82% Upside
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
2.13
Hold$3.83234.79% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.17
Hold$62.509.66% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.00
Buy$68.0078.08% Upside

Current Analyst Ratings Breakdown

Latest ALEC, DNLI, FATE, RVMD, and HALO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$55.00
6/25/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
6/24/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$67.00 ➝ $73.00
6/24/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$57.00
6/12/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/29/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00
5/19/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $27.00
5/14/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$73.00 ➝ $72.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alector, Inc. stock logo
ALEC
Alector
$100.56M1.62N/AN/A$1.29 per share1.27
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$330.53M6.56N/AN/A$8.53 per share1.75
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$13.63M9.63N/AN/A$2.80 per share0.41
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.02B6.92$4.69 per share12.16$2.86 per share19.93
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M614.24N/AN/A$13.47 per share2.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alector, Inc. stock logo
ALEC
Alector
-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$422.77M-$2.67N/AN/AN/AN/A-35.90%-32.41%7/30/2025 (Estimated)
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$186.26M-$1.49N/AN/AN/A-1,318.93%-47.17%-34.60%8/12/2025 (Estimated)
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$444.09M$3.7615.169.160.3844.76%136.91%26.05%8/5/2025 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$600.09M-$4.00N/AN/AN/AN/A-37.06%-32.84%8/6/2025 (Estimated)

Latest ALEC, DNLI, FATE, RVMD, and HALO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.73N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Alector, Inc. stock logo
ALEC
Alector
-$0.45N/AN/AN/A$2.76 millionN/A
8/6/2025Q2 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.14N/AN/AN/A$0.50 millionN/A
8/5/2025Q2 2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.22N/AN/AN/A$282.66 millionN/A
5/13/2025Q1 2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million
5/7/2025Q1 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.12-$1.13-$0.01-$1.13N/AN/A
5/6/2025Q1 2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.71-$0.78-$0.07-$0.78$3.24 millionN/A
5/6/2025Q1 2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$0.98$1.11+$0.13$0.93$231.21 million$264.86 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/AN/AN/AN/AN/A
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alector, Inc. stock logo
ALEC
Alector
0.10
3.34
3.34
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/A
9.56
9.56
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/A
8.81
8.81
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
3.13
8.39
7.30
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/A
13.46
13.46

Institutional Ownership

CompanyInstitutional Ownership
Alector, Inc. stock logo
ALEC
Alector
85.83%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
92.92%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
97.54%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alector, Inc. stock logo
ALEC
Alector
27099.99 million90.89 millionOptionable
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
430145.28 million127.12 millionOptionable
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
550114.60 million108.29 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
390123.22 million120.26 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250186.27 million170.99 millionOptionable

Recent News About These Companies

Leerink Partnrs Issues Positive Estimate for RVMD Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alector stock logo

Alector NASDAQ:ALEC

$1.61 -0.11 (-6.40%)
Closing price 04:00 PM Eastern
Extended Trading
$1.61 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics stock logo

Denali Therapeutics NASDAQ:DNLI

$14.52 -0.83 (-5.41%)
Closing price 04:00 PM Eastern
Extended Trading
$14.52 0.00 (-0.03%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Fate Therapeutics stock logo

Fate Therapeutics NASDAQ:FATE

$1.15 -0.01 (-0.86%)
Closing price 04:00 PM Eastern
Extended Trading
$1.14 0.00 (-0.43%)
As of 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$57.15 -0.48 (-0.83%)
Closing price 04:00 PM Eastern
Extended Trading
$57.16 +0.01 (+0.02%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$38.02 -0.48 (-1.25%)
Closing price 04:00 PM Eastern
Extended Trading
$38.02 -0.01 (-0.01%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.